One-Year estimated GFR Slope Independently Predicts Clinical Benefit in Immunoglobulin A Nephropathy

Abstract

Immunoglobulin A nephropathy (IgAN) is a serious, progressive, immune complex–mediated kidney disease. Being a rare disease, a key challenge for the evaluation of potential new treatments for IgAN is that the progression to end-stage kidney disease typically evolves over many years. Therefore, there is interest in defining earlier surrogate endpoints to serve as reliable predictors of treatment effect on long-term IgAN kidney outcomes.